Value
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 4.9 |
| P/S | 6.6 |
| EV/EBITDA | 0.5 |
| Fwd P/E | 8.6 |
| PEG | 10.0 |
| Analyst target | 5.0 |
- ▸Forward P/E: 13.1x
- ▸PEG: 0.47
NBIX · Why this verdict
Why Neurocrine Biosciences (NBIX) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Neurocrine Biosciences combines a perfect Piotroski F-Score of 9 out of 9, a wide economic moat, and 42% revenue growth at a PEG of 0.45 and forward P/E of 12.5x — making it one of the higher-conviction quality-growth combinations in the specialty pharmaceutical sector — though heavy revenue concentration in a single product line and current negative price momentum create real near-term risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue is growing at 42% year-over-year while the stock trades at a PEG of 0.45 and forward P/E of 12.5x, implying the market is pricing in a significant slowdown that the recent growth rate does not yet support. Growth breakdown | Revenue growth remains above 25% year-over-year for the next 2 quarters, and the PEG remains below 0.80. | →Stable |
| CounterSpecialty pharmaceutical revenue growth is inherently lumpy and often concentrated in the early years of a product lifecycle; the market may be correctly anticipating a deceleration in INGREZZA prescriptions as penetration matures. | ||
Neurocrine Biosciences scores 9 out of 9 on the Piotroski F-Score, carries a wide economic moat rating, and delivers a combination of strong returns and growth that qualifies it as a compounder-quality business — characteristics that historically support long-duration holding periods. Quality breakdown | Quality score remains above 8.0 and the Piotroski F-Score holds at 8 or above over the next 12 months. | →Stable |
| CounterA single-product revenue concentration in INGREZZA means a competitive entry, label restriction, or patent challenge could rapidly erode the moat that underlies the high quality score. | ||
The company has beaten consensus EPS estimates in 3 of the last 4 quarters with an average positive surprise of 2.7%, including a 14.4% beat in the most recent quarter, suggesting disciplined earnings guidance and operational execution. Earnings | Earnings per share beats the consensus estimate in at least 3 of the next 4 quarterly reports. | →Stable |
| CounterThe single quarterly miss of -18.1% was significant in absolute terms, suggesting single-quarter results can be volatile enough to damage sentiment even within a broader beat trend. | ||
Revenue concentration in a single product — INGREZZA — creates a binary risk profile where any adverse regulatory, competitive, or clinical development could materially impair the entire revenue base. Bear case | Pipeline diversification leads to at least 1 additional approved product generating more than 10% of total revenue within 12 months. | →Stable |
| CounterDeep concentration in a single successful product often reflects disciplined capital allocation rather than strategic failure, and INGREZZA's neurology positioning may have a long remaining runway. | ||
Revenue is growing at 42% year-over-year while the stock trades at a PEG of 0.45 and forward P/E of 12.5x, implying the market is pricing in a significant slowdown that the recent growth rate does not yet support.
→StableGrowth breakdown
- Expectation
- Revenue growth remains above 25% year-over-year for the next 2 quarters, and the PEG remains below 0.80.
CounterSpecialty pharmaceutical revenue growth is inherently lumpy and often concentrated in the early years of a product lifecycle; the market may be correctly anticipating a deceleration in INGREZZA prescriptions as penetration matures.
Neurocrine Biosciences scores 9 out of 9 on the Piotroski F-Score, carries a wide economic moat rating, and delivers a combination of strong returns and growth that qualifies it as a compounder-quality business — characteristics that historically support long-duration holding periods.
→StableQuality breakdown
- Expectation
- Quality score remains above 8.0 and the Piotroski F-Score holds at 8 or above over the next 12 months.
CounterA single-product revenue concentration in INGREZZA means a competitive entry, label restriction, or patent challenge could rapidly erode the moat that underlies the high quality score.
The company has beaten consensus EPS estimates in 3 of the last 4 quarters with an average positive surprise of 2.7%, including a 14.4% beat in the most recent quarter, suggesting disciplined earnings guidance and operational execution.
→StableEarnings
- Expectation
- Earnings per share beats the consensus estimate in at least 3 of the next 4 quarterly reports.
CounterThe single quarterly miss of -18.1% was significant in absolute terms, suggesting single-quarter results can be volatile enough to damage sentiment even within a broader beat trend.
Revenue concentration in a single product — INGREZZA — creates a binary risk profile where any adverse regulatory, competitive, or clinical development could materially impair the entire revenue base.
→StableBear case
- Expectation
- Pipeline diversification leads to at least 1 additional approved product generating more than 10% of total revenue within 12 months.
CounterDeep concentration in a single successful product often reflects disciplined capital allocation rather than strategic failure, and INGREZZA's neurology positioning may have a long remaining runway.
Per-dimension breakdown
Quality
8.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 7.5 |
| ROA | 7.7 |
| Gross margin | 8.9 |
| Op margin | 9.1 |
| Net margin | 10.0 |
| Current ratio | 9.8 |
| FCF quality | 6.4 |
| Moat | 9.0 |
| Piotroski F | 10.0 |
- ▸Strong margins: 22%
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
- ▸Strong Piotroski F-Score: 9/9
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 42% YoY
Momentum
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 9.0 |
| Price target | 7.3 |
| erm sentiment | 5.2 |
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Notable insider selling — $55,330,430 (0.331% of mkt cap)
Peer rank
4.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.6 |
| quality rank | 7.8 |
| growth rank | 9.3 |
- ▸Best-in-class margins
- ▸Industry growth leader
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.1 |
| support resistance | 1.6 |
| 52w position | 9.7 |
Risk (lower is worse)
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.4 |
| days to cover | 6.4 |
| volatility | 5.5 |
| put call | 7.3 |
| implied vol | 7.0 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 9.5 |
- ▸Above max pain $140
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 3.8 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.47, quality 8.7/10, growth 10.0/10).
Engine technical detail
verdict_path:
L4:PATH_C2_GARP_WAIT|ENTRY_STICKY:PRIOR_STILL_VIABLEPassed (6)
- MOMENTUM:4.9>=4.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.6<1.5@spot
Warning (2)
- MOMENTUM:4.9<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.59
Upside
+4.7%
Downside
7.8%
Sizing output
STARTER
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The C-path quality+growth combination triggered the STRONG_BUY_WAIT verdict: quality 8.7 and growth 10.0 both clear their thresholds, with asymmetric R:R of 0.59 supporting the read.
The strongest dimensions are Growth at 10.0, Quality at 8.7, and Sentiment at 7.4; the weakest are Insider at 3.4, Technical at 4.1, and Peer rank at 4.9. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.59 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Neurocrine Biosciences scores 9 out of 9 on the Piotroski F-Score, carries a wide economic moat rating, and delivers a combination of strong returns and growth that qualifies it as a compounder-quality business — characteristics that historically support long-duration holding periods.
Trip ifPiotroski F-Score falls below 7 or quality score drops below 7.0.
- P2Revenue is growing at 42% year-over-year while the stock trades at a PEG of 0.45 and forward P/E of 12.5x, implying the market is pricing in a significant slowdown that the recent growth rate does not yet support.
Trip ifRevenue growth falls below 15% year-over-year for 2 consecutive quarters.
- P3The company has beaten consensus EPS estimates in 3 of the last 4 quarters with an average positive surprise of 2.7%, including a 14.4% beat in the most recent quarter, suggesting disciplined earnings guidance and operational execution.
Trip ifThe company misses consensus EPS estimates by more than 15% in 2 of the next 4 quarters.
- P4Revenue concentration in a single product — INGREZZA — creates a binary risk profile where any adverse regulatory, competitive, or clinical development could materially impair the entire revenue base.
Trip ifAny single product accounts for more than 90% of total revenue for 2 consecutive quarters without pipeline progress reducing the dependency.